An Incisive, In-depth Analysis on the Whole Genome Amplification Market
This study offers a comprehensive, 360 degree analysis on the Whole Genome Amplification market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Whole Genome Amplification market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Preference for single-cell whole genome amplification to prevail
Single-cell whole genome amplification is the highly preferred product type in the global market. Advances in primer technologies and lysing techniques have led to more reliable and accurate whole cell genome amplification. Single cell WGA is used to examine the sequence information with the optimized next generation sequencing technologies, only from a single cell. This method is considered to be a powerful tool that helps to understand the ins and outs of genetics by bringing the entire genome structure to a cellular level. Since this method offers a high-resolution view of the genomic sample, its adoption will continue to be on the rise in diverse biological fields such as microbiology, immunology, neurobiology, cancer research, and tissue mosaicism.
Single cell WGA plays a crucial role in conveying new applications to the market. Moreover, screening for a variety of developmental and neurological genetic disorders is heavily dependent on single-cell WGA. These experiments are conducted with an RT-PCR utilizing specific WGA PCR kits. GenomePlex WGA4 kits from Sigma-Aldrich are among a few kits on the market specifically designed for single-cell WGA. Most other kits can be used for either single cells or, more commonly, pool of cells. Leading companies that are dealing in single-cell kits are Sigma-Aldrich (in association with Rubicon Genomics), QIAGEN NV, and GE Healthcare.
According to the market forecast recently provided by Future Market Insights, single-cell WGA Kits are projected to reach a market value of over US$ 2,000 Mn by the end of 2028.
Device & kits manufacturers to abide by FDA’s safety legislations to improve accuracy and efficiency
There is an increase in the safety rules and legislations which is expected to improve accuracy and efficiency significantly. It is also intended to avoid false positivity of whole genome amplification and boost the quality of diagnostic services. To focus more on safety, the U.S. FDA has provided a guideline such as 510-K. This section of Food Drug and Cosmetic Act, also known as Pre-market Approval, recommends device and kits manufacturers to mandatorily register and notify FDA of their intent to promote their product at least 90 days in advance. These improvements are projected to bolster the growth of the global whole genome amplification market.
Introduction of custom product offerings to hit market, as a new strategic move
The research community has to cater to evolving needs, which in turn requires manufacturing of special custom products. The demand for specialized tools and reagents has grown to the point where most vendors currently offering these products cannot depend solely on the sale of the catalog products. The custom requirements demand special time management which depends on the vendor choices. Research users tend to prefer tried-and-tested solutions for their custom reagent needs to avoid the time and effort to validate custom products prior to use in critical experiments.
Product recalls and safety concerns may deter market growth
The process of WGA involves extraction, amplification and sequencing. The PCR-based WGA andREPLI-g technology have different results. Single base-pair mutations, STR contractions, and expansions, and also biased and underrepresented loci are involved in PCR WGA. Whereas, REPLI-g technology, which uses MDA technology and Phi 29 polymerase, delivers highly uniform amplification across the entire genome with minimal locus bias during amplification. This leads to a lack of trust on the process, which declines the revenue of whole genome amplification market.
Global Whole Genome Amplification Market
The global Whole genome amplification market report provides analysis and insights on Whole genome amplification kits and consumables. Commercially available Whole genome amplification kits are based on Single cell WGA kits, Complete WGA Kit, WGA Reamplification Kit, WGA & Chip DNA Kit and others. Increasing demand for technologically advanced methods in sample preparation, extraction, amplification and testing for nucleic acid and the strategic agreements of manufacturers with leading research institutes to boost research activities in molecular biology field play a vital role for fueling the demand of Whole genome amplification. These Whole genome amplification kits can be used in both clinical diagnostics as well as for research applications. Applications such as agricultural and veterinary animal cell DNA testing, viral and bacterial infectious diseases, drug discovery & development, cancerous diseases, forensic testing, genetically related diseases and paternity testing/HLA typing coupled with rising awareness is predicted to increase usages of whole genome amplification worldwide. This is expected to bolster growth of the Whole genome amplification market over the forecast period.
Global Healthcare Sector Outlook
Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.
A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.
FMI utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.
Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.
Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.
Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.
On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.
Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.
By Product Type
By End User